Coagulation parameters for the differential diagnosis of pancreatic cancer in the early stage: a retrospective study
Open Access
- 17 October 2023
- journal article
- research article
- Published by Springer Nature in European Journal of Medical Research
- Vol. 28 (1) , 1-11
Abstract
Background: In recent years, conventional coagulation (CC) and thromboelastography (TEG) parameters have been reported to be closely related to the progression of pancreatic cancer (PC). However, the potential utility of these parameters in differentiating benign and malignant pancreatic diseases is still unclear. Objectives: A retrospective study was conducted to evaluate the efficacy of coagulation parameters in differentiating pancreatic cancer/early stage pancreatic cancer (EPC, TNM stages I and II) from benign control conditions, and to further explore whether coagulation parameters could improve the differential value of CA199. Methods: Receiver operating characteristic (ROC) curves and logistic regression analysis were used to identify the diagnostic value of each coagulation parameter or combination of parameters. Results: Compared with benign pancreatic disease (BPD), patients with pancreatic malignant tumors had significant coagulation disorders, specifically manifested as abnormal increases or decreases in several CC and TEG parameters (such as activated partial thromboplastin time (APTT), fibrinogen (FIB), D-dimer (DD2), K time, R time, Angle, maximum amplitude (MA), coagulation index (CI), and Ly30). In the training group, ROC curve showed that FIB, DD2, Angle, MA, and CI had favorable efficacy at differentiating PC or EPC from BPD (for PC, AUC = 0.737, 0.654, 0.627, 0.602, 0.648; for EPC, AUC = 0.723, 0.635, 0.630, 0.614, 0.648). However, several combined diagnostic indicators based on FIB, DD2 and CI failed to outperform the individual coagulation indexes in diagnostic efficiency. Combinations of certain coagulation indexes with CA199 outperformed CA199 alone at identifying PC or EPC, especially FIB + CA199 (for PC, AUC = 0.904; for EPC, AUC = 0.905), FIB + DD2 + CA199 (for PC, AUC = 0.902; for EPC, AUC = 0.900), FIB + CI + CA199 (for PC, AUC = 0.906; for EPC, AUC = 0.906), and FIB + DD2 + CI + CA199 (for PC, AUC = 0.905; for EPC, AUC = 0.900). The results from a validation set also confirmed that these combinations have advantageous diagnostic value for PC and EPC. Conclusions: A significant hypercoagulable state was common in PC. Some CC and TEG parameters are valuable in the differential diagnosis of benign and malignant pancreatic diseases. In addition, coagulation indexes combined with CA199 can further enhance the differential diagnosis efficacy of CA199 in PC and EPC.Keywords
Funding Information
- Clinical Capability Enhancement Project of Jiangsu Province Hospital (JSPH-MC-2021-4)
This publication has 37 references indexed in Scilit:
- Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancerCancer Science, 2018
- Utility of Viscoelastic Assays Beyond Coagulation: Can Preoperative Thrombelastography Indices Predict Tumor Histology, Nodal Disease, and Resectability in Patients Undergoing Pancreatectomy?Journal of the American College of Surgeons, 2018
- Blood fibrinogen levels discriminate low- and high-risk intraductal papillary mucinous neoplasms (IPMNs)European Journal of Surgical Oncology, 2017
- Potential Biomarkers in Lewis Negative Patients With Pancreatic CancerAnnals of Surgery, 2017
- Reducing Cancer Burden in the Population: An Overview of Epidemiologic Evidence to Support Policies, Systems, and Environmental ChangesEpidemiologic Reviews, 2017
- A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter StudyAmerican Journal of Gastroenterology, 2017
- Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapyPancreatology, 2015
- Validation of Biomarkers That Complement CA19.9 in Detecting Early Pancreatic CancerClinical Cancer Research, 2014
- Clinical Significance of Coagulation Assays in Metastatic Pancreatic AdenocarcinomaJournal of Gastrointestinal Cancer, 2013
- CEA, CA 19‐9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundiceJournal of Surgical Oncology, 2007